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Abstract
Background: The uncemented Nottingham Total Shoulder Replacement prosthesis system (Nottingham
TSR) was developed from the previous BioModular® shoulder prosthesis taking into consideration the
causes of the initial implant's failure.
We investigated the impact of changes in the design of Nottingham TSR prosthesis on its survivorship rate.
Methods: Survivorship analyses of three types of uncemented total shoulder arthroplasty prostheses
(BioModular®, initial Nottingham TSR and current Nottingham TSR systems with 11, 8 and 4 year
survivorship data respectively) were compared. All these prostheses were implanted for the treatment of
disabling pain in the shoulder due to primary and secondary osteoarthritis or rheumatoid arthritis. Each
type of the prosthesis studied was implanted in consecutive group of patients – 90 patients with
BioModular® system, 103 with the initial Nottingham TSR and 34 patients with the current Nottingham
TSR system.
The comparison of the annual cumulative survivorship values in the compatible time range between the
three groups was done according to the paired t test.
Results:  The 8-year and 11-year survivorship rates for the initially used modified BioModular®
uncemented prosthesis were relatively low (75.6% and 71.7% respectively) comparing to the reported
survivorship of the conventional cemented implants. The 8-year survivorship for the uncemented
Nottingham TSR prosthesis was significantly higher (81.8%), but still not in the desired range of above 90%,
that is found in other cemented designs. Glenoid component loosening was the main factor of prosthesis
failure in both prostheses and mainly occurred in the first 4 postoperative years. The 4-year survivorship
of the currently re-designed Nottingham TSR prosthesis, with hydroxylapatite coating of the glenoid
baseplate, was significantly higher, 93.1% as compared to 85.1% of the previous Nottingham TSR.
Conclusion: The initial Nottingham shoulder prosthesis showed significantly higher survivorship than the
BioModular® uncemented prosthesis, but lower than expected. Subsequently re-designed Nottingham TSR
system presented a high short term survivorship rate that encourages its ongoing use
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Background
Inflammatory or degenerative processes of glenohumeral
joint lead to pain and restriction of movements of the
shoulder. Prosthetic replacement of the glenohumeral
joint has gained in popularity because of its efficacy in
relieving pain. The pioneering successful prostheses for
total shoulder arthroplasty have been based on an uncon-
strained design, i.e. a metal spherical head component
fixed to a metal intramedullary stem articulating with a
high-density polyethylene socket (Table 1). These compo-
nents are stabilized in the adjacent bone using polymeth-
ylmethacrylate bone cement [1]. The important cause for
failure of the cemented prostheses was related to the gle-
noid component, with a 0.01–6% rate of loosening [2-4].
The long term survivorship of the prosthesis developed by
C. Neer for the cemented total shoulder arthroplasty
(TSA) is almost the single one with well documented out-
comes [5] with 87% fifteen year survivorship rate for Neer
I & II cemented shoulder prostheses. This implant has
become the gold standard, against which all the successive
prosthetic designs are compared.
Further developments of TSA implants have been aimed
at enhancing longevity by addressing the following three
most critical issues: (1) Improving the incorporation of
the glenoid component using a more "biological" type of
fixation in order to reduce the rate of mechanical loosen-
ing; (2) Designing a better glenoid component to achieve
the lowest possible rate of wear; (3) Finding the best
method for the fixation of the humeral component while
allowing good preservation of the humeral bone stock,
taking into consideration need for possible future revision
surgery.
These goals can potentially be achieved using an unce-
mented design, with press fit and/or tissue in-growth
porous coating of the metal, at its bone interface. There is
evidence that the porous coating at the proximal part of
the stem is superior to the press fit design [6], possibly
because of lesser stress shielding of the proximal humerus
and subsequently less bone resorption, and preservation
of the proximal humeral bone stock. Biological fixation of
the glenoid component currently requires the use of a
metal backing or metal base-plate that serves as the "bone
in-growth" surface and results in a more even distribution
of the compression forces on the bone. On this baseplate
a high-density polyethylene insert is mounted, either
molded onto the metal or fixed using some form of fas-
tening mechanism at the time of surgery. This bearing
should be at least 3 mm thick (at its thinnest part) to
reduce polyethylene wear [2,7].
Currently there are very few long-term peer reviewed large
series survivorship data on cemented TSAs [5,8] and no
survivorship data on cementless designs (Table 1). Survi-
vorship studies with commonly acceptable clinical out-
come criteria are important, but currently there is no
uniform agreement on these types of criteria. Most
authors consider revision of the prosthesis an end point in
its survivorship [9]. Furthermore published reports on
single prosthetic designs so far have only provided short-
term postoperative follow-up data or a small number of
patients. All these factors result in wide confidence inter-
vals in survivorship tables and lead to difficulty in draw-
ing a meaningful interpretation of the results [9].
In spite of these problems we can reach some tentative
conclusions from TSA outcome by different authors
(Table 1). The best long-term outcome is that reported for
the Neer II cemented prosthesis, with a 93% ten years sur-
vivorship. Short-term glenoid failure, requiring implant
removal, reaches the rate of around 6% for cemented
designs and 3% for cementless designs. Glenoid failure is
the cause of between 20% – 50% of all failed TSAs,
cemented or cementless. Survivorship of cemented TSA is
highest in patients with rheumatoid arthritis. We are nor
aware of survivorship data available for rheumatoid
patients with cementless designs. It is logical to conclude
that any cementless prosthetic design should possess at
least the best survivorship characteristics of the cemented
prostheses in order to be considered as an alternative.
Table 1: Long term survivorship data on cemented and the outcome of a large series of a cementless total shoulder replacement 
prostheses




Tarchia, Cofield & 
Settergren [5]
Neer I & II cemented 113
[31 = OA, 36 = RA 12 = 2ary OA]
10years = 93%
15years = 87%
Revision – severe pain, abd 
< 90°, ext rot < 20°
7/113 14/113
Brenner, Perlic, 
Clayton & Dennis [8]
Neer II & Gristina 
cemented
51
[37 = OA 14 = RA]
11years = 75% Severe pain, radiographic 
evidence of component 
loosening
3/51 6/51
Cofield [6] Cofield cementless 180
[110 = OA 28 =RA 30 = 2ary OA 12 = 
revisions]
Not calculated Revision 5/180 12/180
Pfahler et al [4] Aequalis cemented 705
[418 = OA 107 = RA 180 = 2ary OA]
Not calculated Revision 9/705 43/705
OA = osteoarthritis, RA = rheumatoid arthritisBMC Musculoskeletal Disorders 2007, 8:76 http://www.biomedcentral.com/1471-2474/8/76
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In order to achieve the goal of the desired survivorship
rates of cementless TSA a chain of modification of the ini-
tial BioModular® prosthesis was employed with eventual
evolvement of the current Nottingham TSR design. The
main characteristics of this prosthesis are: (1) The use of
an indexable offset modular head, to improve the ana-
tomical configuration of the implant and the optimal soft
tissue balancing [10,11]. (2) A porous proximal stem in
order to eliminate the stress shielding effect. (3) Con-
formed radii of humeral and glenoid components in
order to reduce point loading and point wear of the poly-
ethylene glenoid liner [12]. (4) Hydroxyapatite lining of
the glenoid baseplate-bone interface in order to provide a
"biologic" milieu to improve an osseo-integration [13].
The BioModular® total shoulder arthroplasty prosthetic design is shown Figure 1
The BioModular® total shoulder arthroplasty prosthetic design is shown. (A) A titanium BioModular® stem. (B) An offset "Wal-
lace" head. (C) The glenoid trays: on the right – the low-profile version, top row – view from the side, bottom row – view into 
the tray, showing the glenoid liner capture mechanisms.
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(5) An improved capture mechanism for holding the pol-
yethylene bearing onto the base-plate in order to reduce
the liner disengagement rate. Following these design
changes we hypothesize that the TSA with cementless
implantation will present improved survivorship rates.
Therefore in order to estimate the improvement in a per-
formance of the prostheses design we have compared sur-
vivorship data of the BioModular® prosthesis – with or
without the "Wallace" prototype offset head (Fig 1) – with
the survivorship of the initial design of the Nottingham
TSR (Fig 2) and the latest design of the Nottingham TSR
with the glenoid component base-plate covered by
hydroxyapatite (Fig 3). We show that Nottingham TSR
uncemented prosthesis has better short and midterm sur-
vivorship than the BioModular® uncemented design.
The Nottingham TSR total shoulder arthroplasty prosthetic design is shown Figure 2
The Nottingham TSR total shoulder arthroplasty prosthetic design is shown. (A) A chrome cobalt stem. (B) A glenoid tray 
showing the capture mechanism for the polyethylene liner. (C) A glenoid tray seen from the back, showing the areas for bone 
in-growth. (D) An off-set head with a morse taper assembling interface.
AB
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Methods
Survivorship analyses of three types of uncemented TSA
prostheses, implanted for the treatment of disabling pain
in the shoulder due to primary and secondary osteoarthri-
tis or rheumatoid arthritis, were compared. Each type of
the prosthesis studied was implanted in consecutive
group of patients, i.e. Group 1: the BioModular® TSA pros-
thesis, Group 2: The initial Nottingham TSR prosthesis
and Group 3: The most recently redesigned Nottingham
TSR prosthesis. The indication for surgery and criteria for
inclusion in the study were pain in the shoulder with
functional disability combined with radiographic evi-
dence of an advanced destruction of the humeral and gle-
noid articular surfaces. Patients compatible with these
criteria but who were medically unfit for surgery, due to
advanced systemic disease, were not offered the procedure
and were therefore excluded from the study.
Group 1 was comprised of 90 patients who were operated
between 1989–1994 (15 men and 75 women, mean age
61 years, range 19 – 92 years). These patients had the
uncemented BioModular®  Total Shoulder Prostheses
implanted, either with the standard non-offset head or the
prototype ("Wallace") offset humeral head. The mean fol-
low up period in this group was 8.8 years.
Group 2 patients were treated with the initial Nottingham
TSR cementless prosthesis where the glenoid component
had no hydroxyapatite backing. This group included 103
patients – 12 men and 91 women, average age of 58 years
(range: 20–84 years). This design has been used between
1994 and 1997 and the patients had a mean follow up
period of 6.4 years.
Group 3 comprised of 34 patients, who had a hydroxyap-
atite coated glenoid component base plate implanted, as
part of their most recent Nottingham TSR. In this group
there were two men and 32 women, with a mean age of
64 years (range 31–89 years). These patients were oper-
ated in 1998–99 and had a mean follow up of 3.2 years.
Table 2: Characteristics of the study groups
Study Group Age (years) Male/Female Mean follow up (years) OA RA 2ndary OA Total Number
Group 1 Mean: 61 Range: 19–92 15/75 8.8 48 (1 with RC tear) 31 (2 with RC tear) 11 90
Group 2 Mean: 58 Range: 20–84 12/91 6.4 47 36 (2 with RC tear) 20 103
Group 3 Mean: 64 Range: 31–89 2/32 3.2 19 12 (1 with RC tear) 3 34
OA = osteoarthritis, RA = rheumatoid arthritis, RC – rotator cuff muscle
The Nottingham TSR total shoulder arthroplasty prosthetic design with glenoid base-plate coated with hydroxyapatite Figure 3
The Nottingham TSR total shoulder arthroplasty prosthetic design with glenoid base-plate coated with hydroxyapatite. (A) A 
lateral view of the base-plate with fixation screws and with mounted polyethylene liner. (B) A view on the bone interface side 
of the base-plate covered by hydroxyapatite.
ABBMC Musculoskeletal Disorders 2007, 8:76 http://www.biomedcentral.com/1471-2474/8/76
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The characteristics of the different groups of patients are
given in the Table 2. All these patients were included in
the survivorship analyses.
For the comparison of the three TSA prostheses' clinical
outcome we used a survivorship analysis according to the
method described by Murray et al [14] which is based on
Rothman's formula for the confidence limits determina-
tion. The criterion for failure in this series was revision
surgery requiring removal or exchange of either part of or
a whole prosthesis. The indications for these re-operations
were: (1) An increased level of pain during follow-up, that
appeared to be related to the implant, with restriction of
external rotation to under 20° and abduction to under
60° and/or newly developed radiolucency around the gle-
noid peg or complete peri-prosthetic radiolucency at the
metal-bone interface, more then 2 mm in width, around
either the humeral or glenoid components [7]. The radio-
graphic evaluation was done by the surgical team and by
the radiologist; (2) Deep wound infection; (3) Migration
of any of the prosthetic components.
For the purpose of postoperative follow up and identifica-
tion of the possible failure of the implants the patients
were monitored annually. This review evaluation
included estimation of the level of pain using a Visual
Analog Scale, a clinical examination of the range of move-
ments of the shoulder and radiographic evaluation of the
shoulder with an anterior – posterior view and an axillary
view to allow assessment of the alignment and position of
the components, the presence of any change in position
over time and measurement of any radiolucency at the
prosthesis-bone interface.
Information on patients who died during the follow up
period, which is included in the survivorship analysis, was
obtained either from the Registrar for Births, Marriages
and Deaths or from the hospitals' registration systems and
through direct contact with General Practitioners or rela-
tives.
The comparison of the annual cumulative survivorship
values (quantitative type of variables) in the compatible
time range between the three groups was done according
Table 3: Time distribution of the occurrence of prostheses failure in the Group 1 (patients operated in 1989 – 94 with BioModular® 
uncemented TSA) according to the mode of failure
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Table 4: Time distribution of the occurrence of prostheses failure in the Group 2 (patients operated in 1994 – 97 with the initial 
Nottingham TSR prosthesis) according to the mode of failure
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to the paired t test and the p < 0.05 was considered signif-
icant.
The TSA operations were performed through a proximally
extended deltopectoral approach with a longitudinal clav-
icle osteotomy and a lesser tuberosity osteotomy [15].
This approach was used to facilitate glenoid exposure and
to ensure stable deltoid and subscapularis muscle reat-
tachment, that allows early postoperative shoulder mobi-
lization [16]. The authors prefer this surgical approach
also because it protects the deltoid muscle during retrac-
tion. After humeral head resection, humeral stem align-
ment was established using the anatomical neck as a guide
to prosthesis placement, preserving the rotator cuff.
Humeral medullary canal and glenoid surface preparation
were carried out using specially designed reamers. With
the standard BioModular® stems either a standard or an
offset prototype modular head was used. The head geom-
etry, apart from the off-set feature, was identical in the two
types of prostetic heads used with the BioModular®
implant. In the Nottingham TSR system humeral stems in
four sizes, offset modular heads in five sizes and glenoid
bearings in three thicknesses were available for optimal
component fitting and soft tissue balancing. In six
patients (three in the Group 1, two in the Group 2 and
one patient in the Group 3 – Table 2) tears in rotator cuff
muscles were identified and firmly repaired. Five of six
patients with rotator cuff muscles tears suffered from the
rheumatoid arthritis.
During the first three months postoperatively every
patient underwent intensive physiotherapy following a
standard programme aimed at improving strength and
range of movements. Since the surgical procedure was car-
ried out through a deltopectoral approach with a lesser
tuberosity osteotomy and its strong reattachment, an
immediate postoperative rehabilitation was possible with
very few limitations. Usually a work on external rotation
and elevation was commenced from the first postopera-
tive day with isometrics, passive and active elevation and
external rotation up to the level of movement achieved
during the surgery. Patients used the broad arm sling
intermittently only during the first 2–3 postoperative
days. The exercise programme was increased as the
patients gain confidence and pain relief aiming to achieve
a maximal possible active and passive range of move-
ments.
Results
The eight year survivorship of the initial Nottingham TSR
design (Group 2) was higher (p < 0.001) than observed in
Group 1 patients with implanted BioModular® prostheses
(Fig 4,5). The eight-year cumulative survivorship in the
Group 2 was 81.8% and remained constant from the sixth
postoperative year (Fig 5). The eight – and ten- year cumu-
lative survival rates of Group 1 (BioModular® prosthesis)
were 75.6% and 71.7% (Fig 4). The main causes of failure
of the BioModular® prosthesis were related to the glenoid
component, i.e. aseptic glenoid component loosening in
13 patients and uncoupling of the polyethylene bearing
liner in 4 patients, overall 71% of failed cases (Table 3).
Seventy one percent of the failed cases occurred during the
first four postoperative years (Table 3) showing four year
cumulative survivorship rate of 80.9% (Fig 4). The main
This graph shows the survival results of BioModular® total  shoulder arthroplasty (vertical bars represent 95% confi- dence intervals) Figure 4
This graph shows the survival results of BioModular® total 
shoulder arthroplasty (vertical bars represent 95% confi-
dence intervals).







































Table 5: Failed uncemented Nottingham TSR prostheses in Group 2 (patients operated in 1994 – 97) according to their mode of 
failure
Component Mode of Failure
Loosening Infection Malposition: bearing failure/
head dislocation, stem 
malposition
Glenoid 8 (OA = 4, RA = 2, 2ndary OA = 2) 07   [OA = 4, 2ndary OA = 3]
Humeral 0 0 2 [2ndary OA = 2]
OA = osteoarthritis, RA = rheumatoid arthritisBMC Musculoskeletal Disorders 2007, 8:76 http://www.biomedcentral.com/1471-2474/8/76
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drop in survivorship of the initial Nottingham TSR
occurred also during the initial four postoperative years
and was mainly due to glenoid component failure (11 of
the 17 failed cases, Table 4). About half of the failures in
Group 2 during the eight years of the survivorship analysis
were due to aseptic loosening of the glenoid base-plate in
eight patients, six of these patients were treated for pri-
mary or secondary osteoarthritis (Table 5).
Survivorship in patients with rheumatoid arthritis (RA) in
both groups 1 and 2 was higher (p < 0.001) than in
patients with osteoarthritis. The patients with RA who had
the BioModular® prosthesis implanted, presented a
96.8% and 93.1% cumulative five and eight year survivor-
ships respectively (Fig 6) and the RA patients with the ini-
tial Nottingham TSR had presented a constant 94.4%
cumulative survivorships from the fourth to eights year
postoperatively (Fig 7).
The initial Nottingham TSR prostheses showed higher
eight year survivorship than BioModular® prostheses in
patients with OA (p < 0.01). Survivorship of the BioMod-
ular® prosthesis in patients with primary osteoarthritis was
70.9% and 64.3% at five and eight years respectively and
for the initial Nottingham TSR these values were 84.5%
and 80.4% (Fig 8,9).
The observed four-year survivorship of the patients in
Group 3 was also significantly higher than the survivor-
ship rates of the BioModular® prosthesis observed after the
first four years after implantation (p = 0.02), with a 93.1%
cumulative four year survivorship of the re-designed Not-
tingham TSR (Fig 10) comparing to the 80.9% of cumula-
tive four year survivorship of the BioModular® prosthesis
(Fig 4). Among the Group 3 patients only two prostheses
failed, both in patients with osteoarthritis (Table 6). One
failure was due to glenoid bearing disassembly, two years
after the operation, and the other due to glenohumeral
dislocation three years after the operation (Table 7).
Discussion
The evolving cementless TSA prostheses should present
longevity that is comparable with or better than conven-
tionally used cemented implants. We evaluated the short
and midterm survivorship of the Nottingham TSR
cementless prosthesis, with comparison to the survivor-
ship of the BioModular® TSA prosthesis from which the
Nottingham TSR evolved, in order to estimate the ability
of these implants to achieve the desirable survivorship
rates. The transitions from one design to another occurred
following recognition of causes of implant failure. The use
of the offset head on the standard BioModular® stem
design did not prevent a considerably high loosening rate.
The subsequent change to a conforming design with an
identical radii of curvature of the humeral head compo-
nent and glenoid component and to a different glenoid
component with a conical peg, allowing press-fit implan-
tation, led to significant improvement in the middle term
survivorship among the patients who had an implant of
the initial Nottingham TSR design. We are aware of sug-
gestions by other authors, that full conformity between
the components may lead to an enhanced stress on the
globoid rim due to loss of the humeral head translation
possible in the normal shoulder joint, and as a conse-
quence a higher risk for prosthetic loosening. [12,17].
Since this hypothesis has been raised following cadaveric
studies and in vivo radiographic evaluation and has been
never confirmed in clinical trials and since the exact
degree of optimal mismatch of the glenoid and the
humeral head radii is not known, the authors preferred
the conforming design. This choice of conformity is based
This graph shows the survival rate of the initial design for the  Nottingham TSR (vertical bars represent 95% confidence  intervals) Figure 5
This graph shows the survival rate of the initial design for the 
Nottingham TSR (vertical bars represent 95% confidence 
intervals).







































Table 6: Failed uncemented Nottingham TSR prostheses in the Group 3 (patients operated in 1998 -99) according to the mode of 
failure
Component Mode of Failure
Loosening Infection Malposition: bearing failure/
head dislocation
Glenoid 0 0 2 (OA = 2)
H u m e r a l 000
OA = osteoarthritisBMC Musculoskeletal Disorders 2007, 8:76 http://www.biomedcentral.com/1471-2474/8/76
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on the hypothesis that mismatch of the glenoid and
humeral component curvature can lead to a considerable
rate of polyethylene wear due to uneven force distribution
between the components and point loading and point
wear of the polyethylene [12].
The midterm survivorship in the Group 2 patients shows
that the original Nottingham TSR had less favorable
results when compared with the existing published survi-
vorship studies on the Neer I & II cemented implants [5],
with the outcome studies of the Cofield uncemented pros-
theses [6] and with the "Aequalis" cemented prosthesis
[4], but is comparable with the study on the Neer II and
Gristina prostheses [8]. The comparison with the latter
study is more realistic because the groups of patients are
more comparable to our patients, i.e.both series consist
mainly of patients with primary osteoarthritis, smaller
groups of patients with rheumatoid arthritis and some
patients with secondary osteoarthritis, and they have sim-
ilar indications for failure recognition. Although the mid-
term survivorship of the initial Nottingham TSR design
showed a significant improvement over the survivorship
rate of the BioModular®  prosthesis, especially in the
patients with osteoarthritis, this improvement did not
reach the desired values of survivorship above 90% that
has been reported for the cemented Neer I&II prostheses.
We note that the overall lower than desired midterm sur-
vivorship rates in the Group 2 patients are due to less favo-
rable performance of the Nottingham TSR prosthesis in
patients with primary osteoarthritis, who had an eight
year survivorship rate of only 80.4%. The interesting find-
ing is the evidence of a significantly higher (and in the
desirable range of above 90%) survivorship in patients
with rheumatoid arthritis compared to the patients with
osteoarthritis in both Group 1 and Group 2. The differ-
ence in the survivorship between patients with osteoar-
thritis and rheumatoid arthritis is consistent with
observations in other reports on other prosthetic shoulder
arthroplasty systems [8] and can be explained by the
lower level of demand placed on a shoulder prostheses in
a rheumatoid patient.
In spite of the improved survivorship in the initial design
of the Nottingham TSR it still showed an unsatisfactory
short term loosening rate. It should be realized that the
two most serious complications of any prosthetic surgery,
e.g. deep wound infection and periprosthetic fracture, did
not occur among any of the patients treated by the initial
design of the Nottingham TSR. This can probably be
attributed to the use of an appropriate surgical technique
and instrumentation for the prosthesis implantation. The
glenohumeral dislocation rate appeared to be similarly
low in Group 1, five of 90 patients, and Group 2, four of
103 patients, (Tables 3,4). This finding shows that the tis-
sue balancing technique for the Nottingham TSR prosthe-
sis implantation, i.e. systematic intraoperative evaluation
of an adequate free subacromial space, flush and stable
alignment of the glenoid and humeral components with
This graph shows the survival rate of the initial design of the  Nottingham TSR in patients with RA (vertical bars represent  95% confidence intervals) Figure 7
This graph shows the survival rate of the initial design of the 
Nottingham TSR in patients with RA (vertical bars represent 
95% confidence intervals).
Survival of the Nottingham Total Shoulder 







































This graph shows the survival rates of the BioModular® total  shoulder arthroplasty in patients with RA (vertical bars rep- resent 95% confidence intervals) Figure 6
This graph shows the survival rates of the BioModular® total 
shoulder arthroplasty in patients with RA (vertical bars rep-
resent 95% confidence intervals).
Survival of the BioModular® Total Shoulder 






































This graph shows the survival results of the BioModular®  total shoulder arthroplasty in patients with OA (vertical bars  represent 95% confidence intervals) Figure 9
This graph shows the survival results of the BioModular® 
total shoulder arthroplasty in patients with OA (vertical bars 
represent 95% confidence intervals).
Survival of the BioModular® Total Shoulder Prosthesis  in 
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correct offset of the humeral head, adequate anterior –
posterior laxity and ability to reattach the lesser tuberosity
with the arm in external rotation without loosing of the
desired glenohumeral reduction, was effective.
The main mode of failure of the prostheses in Group 2
patients was aseptic loosening of the glenoid component
predominantly occurring in the first four postoperative
years and the second most important cause of failure
cause bearing disassembly during the same postoperative
period (Table 4). After having identified the two main
causes of failure for the intermediate design of the Not-
tingham TSR prosthesis, steps were taken to change of the
design of the metal base-plate of the glenoid component.
To achieve an optimal bone osseointegration coating of
the implant with hydroxyapatite was introduced. In order
to eliminate glenoid bearing disassembly improvement of
the capture mechanism for the glenoid bearing was impli-
mented. When looking at the data for Group 3, the addi-
tion of hydroxyapatite to the porous coating of the
glenoid base-plate has eliminated the original 3.9–5.6%
rate of aseptic glenoid loosening from the second to the
fourth postoperative years (Tables 3, 4, 7). Additionally
by improving the capture mechanism of the glenoid bear-
ing its disassembly has now became rare (Tables 3, 4, 7).
Following these changes in design the four-year survivor-
ship of the Nottingham TSR prostheses in the Group 3
patients showed a satisfactory 93.1 % rate, which is signif-
icantly higher than the four-year survivorship rates of the
BioModular® system. Since in the Groups 1 and 2 the dete-
rioration in the survivorships occurred predominantly in
the first four postoperative years, the present high four-
year survivorship rate of the newly designed prosthesis
might indicate on a sustained long-term improvement of
the prosthesis survivorship.
Since Group 3 comprised of only 34 patients we have not
subdivided and compared the subgroups according to the
underlying pathology as we did in Groups 1 and 2. Fur-
thermore, because the number of patients in Group 3 is
not sufficient for the adequate power of the statistical
comparison with the survivorship in Group 2 patients we
can only suggest that the further improvement of the
present Nottingham TSR system survivorship is likely to
be seen. Future long-term survivorship studies will verify
this point more precisely. However, with regard to its ini-
tial design (Group 2), there is a clear evidence that the
cementless Nottingham TSR system led to a significant
improvement in its midterm survivorship comparing to
its predecessor, the BioModular® prosthesis.
Conclusion
We have shown that the discussed cementless TSA pros-
thesis design (Nottingham TSR), following a chain of
This graph shows the survival of the current Nottingham TSR  with a hydroxyapatite coated glenoid baseplate (vertical bars  represent 95% confidence intervals) Figure 10
This graph shows the survival of the current Nottingham TSR 
with a hydroxyapatite coated glenoid baseplate (vertical bars 
represent 95% confidence intervals).







































Table 7: Time distribution of the occurrence of prostheses failures in the Group 3 (patients operated in 1998 – 99 with the current 
Nottingham TSR prosthesis) according to the mode of failure






This graph shows the survival rate of the initial design for the  Nottingham TSR in patients with OA (vertical bars represent  95% confidence intervals) Figure 8
This graph shows the survival rate of the initial design for the 
Nottingham TSR in patients with OA (vertical bars represent 
95% confidence intervals).
Survival of the Nottingham Total Shoulder 
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modifications according to recognition of previous causes
of failure, have reached short term survivorship rates that
are comparable to the conventional cemented designs.
Therefore, in the light of potential long term "biological"
advantages of uncemented implants, these results are
encouraging for the ongoing use and development of this
type of prosthesis.
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